Clinical trials: Left Ventricular Failure
Cardiogenic Shock, Heart Failure
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with cardiogenic shock due to isolated or predominant left…
- Conditions
- Cardiogenic Shock, Heart Failure, Acute Myocardial Infarction (AMI)
- Trial name
- NCT07293923
- Testing
- Elevate™ System
- Where
- 8 sites in Georgia, Israel
- Volunteers
- 10 people
- Sponsor
- Magenta Medical Ltd.
Heart Failure
Left Ventricular Capture Management (LVCM) Software Download Clinical Trial
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes.
- Trial name
- NCT00268281
- Testing
- Left Ventricular Capture Management Software
- Where
- 18 sites in United States
- Volunteers
- 107 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Anemia, Kidney Failure
A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.
The purpose of this study is to determine if using Eprex, to maintain hemoglobin within the normal range, will prevent or delay the progression of left ventricular mass growth.
- Conditions
- Anemia, Kidney Failure, Left Ventricular Hypertrophy
- Trial name
- NCT00364260
- Testing
- epoetin alfa
- Volunteers
- 172 people
- Sponsor
- Janssen-Ortho Inc., Canada
Chronic Heart Failure
Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
The purpose of this study is to evaluate the safety and effectiveness of the HeartWare® LVAD System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death.
- Trial name
- ADVANCE (NCT00751972)
- Testing
- HeartWare® VAS
- Where
- 35 sites in United States
- Volunteers
- 140 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Symptomatic Decompensated Congestive Heart Failure, Congestive Heart Failure in Acute Coronary Syndrome
A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.
The purpose of this study is to compare the hemodynamic (blood flow) and clinical effects of the study drug, Natrecor (nesiritide, a recombinant form of the natural human peptide normally secreted by the heart in response to…
- Trial name
- NCT00270374
- Testing
- nesiritide
- Volunteers
- 498 people
- Sponsor
- Scios, Inc.
Refractory Heart Failure, Cardiovascular Diseases (CVD)
European Study of the BrioVAD Heart Pump for Advanced Heart Failure
This clinical investigation evaluates the safety and clinical performance of the BrioVAD Left Ventricular Assist System in patients with advanced, refractory left ventricular heart failure who require mechanical circulatory…
- Trial name
- BRIOLIFE (NCT07252531)
- Testing
- LVAD implantation
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- BrioHealth BV
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function
- Trial name
- NCT00634400
- Testing
- Candesartan
- Volunteers
- 6,268 people
- Sponsor
- AstraZeneca
Current or Recent History of Atrial Fibrillation
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who…
- Trial name
- GENETIC-AF (NCT01970501)
- Testing
- bucindolol hydrochloride, metoprolol succinate
- Where
- 97 sites in United States, Canada and 4 more
- Volunteers
- 267 people
- Sponsor
- ARCA Biopharma, Inc.
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
PORTHOS - PORTuguese Heart Failure Observational Study
This study aims to determine the prevalence of heart failure in the resident population in mainland Portugal aged 50 years or above, using a contemporary, guideline-based diagnostic approach, to optimize patient management and…
- Trial name
- PORTHOS (NCT05434923)
- Where
- 13 sites in Portugal
- Volunteers
- 6,189 people
- Sponsor
- AstraZeneca
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
End-Stage Heart Failure, Cardiomyopathies
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
The purpose of this trial is to determine the safety and feasibility of the VentrAssist LVAD in providing circulatory support for patients who require an LVAD as a bridge to cardiac transplantation.
- Trial name
- NCT00490347
- Testing
- VentrAssist Left Ventricular Assist Device
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Ventracor
Heart Failure, Anemia
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in…
- Conditions
- Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction
- Trial name
- NCT00358215
- Testing
- Darbepoetin alfa
- Where
- 754 sites in United States, Argentina and 34 more
- Volunteers
- 2,278 people
- Sponsor
- Amgen
Heart Failure
The Product Surveillance Registry REVERSE Post Approval Study
The purpose of the REVERSE Post Approval Study (PAS) is to confirm the benefit observed in the REVERSE and RAFT pivotal studies in "real-world" clinical practice.
- Trial name
- PSR-REVERSE (NCT01660035)
- Where
- 123 sites in United States, Belgium and 8 more
- Volunteers
- 155 people
- Sponsor
- Medtronic
Heart Failure, Congestive
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
- Trial name
- REMODEL (NCT00082589)
- Testing
- Eplerenone
- Where
- 53 sites in United States
- Volunteers
- 250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Congestive Heart Failure, Type II Diabetes Mellitus
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III).
- Trial name
- NCT00894868
- Testing
- vildagliptin
- Where
- 93 sites in Czechia, Denmark and 13 more
- Volunteers
- 798 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure.
- Trial name
- 8212-Preserved (NCT06979362)
- Testing
- CDR132L
- Where
- 118 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Heart Failure
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more.
- Trial name
- NCT06424288
- Testing
- vicadrostat, empagliflozin
- Where
- 671 sites in United States, Argentina and 28 more
- Volunteers
- 6,712 people
- Sponsor
- Boehringer Ingelheim